Radiation-induced Esophagitis Pipeline Assessment (2023 Updates) | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Competitive Landscape, Treatment Outlook, and Key Companies

Las Vega (Nevada), United States //- "Radiation-induced Esophagitis Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Radiation-induced Esophagitis Therapeutics Market.

The report provides a detailed description of the Radiation-induced Esophagitis drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any).

The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Get a Detailed Overview of the Radiation-induced Esophagitis Clinical Trial Activities and Regulatory Developments in the domain:
https://www.delveinsight.com/report-store/radiation-induced-esophagitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Radiation-induced Esophagitis Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing Radiation-induced Esophagitis therapies.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Radiation-induced Esophagitis treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging Radiation-induced Esophagitis drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Radiation-induced Esophagitis treatment market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Learn More about the Clinical and Commercial Development Activities in the Radiation-induced Esophagitis Therapeutics Domain:
https://www.delveinsight.com/report-store/radiation-induced-esophagitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

The Report Covers the Emerging Radiation-induced Esophagitis Therapies Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration
Radiation-Induced Esophagitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Subcutaneous
• Intravenous
• Oral
• Intramuscular

Molecule Type
Products have been categorized under various Molecule types such as
• Small molecules
• Natural metabolites
• Monoclonal antibodies

Request for Sample PDF to Understand More About the Radiation-induced Esophagitis Treatment Outlook and Future Perspectives:
https://www.delveinsight.com/sample-request/radiation-induced-esophagitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Radiation-induced Esophagitis Therapeutics Analysis
Radiation esophagitis is a common, dose-limiting, early adverse effect of radiation treatment of thoracic tumors. Its incidence is greater with higher radiation doses and concurrent chemotherapy. Early symptoms, usually following two to three weeks of treatment, include dysphagia and odynophagia. Topical anesthetics such as viscous lidocaine (Xylocaine), proton pump inhibitors, and promotility agents may provide symptomatic relief. Dietary modifications shown to reduce incidence and severity include a bland diet and avoidance of alcohol, coffee, and acidic foods.

The emerging drugs landscape does not represent a particularly promising picture due to the lack of later-stage clinical products, which is quite evident based on the scarcity of clinical trials being conducted for the pivotal stage.

Currently, Galera Therapeutics is developing GC4419 (also known as avasopasem manganese), which is a highly selective small molecule superoxide dismutase (SOD) mimetic designed to protect normal tissues from radiation-induced damage. The company is conducting a Phase IIa clinical study to evaluate the efficacy of GC4419 in lowering the incidence of radiation-induced esophagitis among lung cancer patients. In January 2020, the company dosed the first patient in a Phase IIa clinical trial of avasopasem manganese (GC4419).

Get an in-depth Assessment of the Emerging Therapies and Radiation-induced Esophagitis Companies Actively Working in the Market:
https://www.delveinsight.com/sample-request/radiation-induced-esophagitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content
1. Report Introduction
2. Executive Summary
3. Radiation-induced Esophagitis Current Treatment Patterns
4. Radiation-induced Esophagitis - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Radiation-induced Esophagitis Late-Stage Products (Phase-III)
7. Radiation-induced Esophagitis Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Radiation-induced Esophagitis Discontinued Products
13. Radiation-induced Esophagitis Product Profiles
14. Radiation-induced Esophagitis Companies
15. Radiation-induced Esophagitis Drugs
16. Dormant and Discontinued Products
17. Radiation-induced Esophagitis Unmet Needs
18. Radiation-induced Esophagitis Future Perspectives
19. Radiation-induced Esophagitis Analyst Review
20. Appendix
21. Report Methodology

Get Detailed Insights About the Reports Offerings:
https://www.delveinsight.com/sample-request/radiation-induced-esophagitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.